Bolt Biotherapeutics, Inc.
BOLT· Nasdaq
Released Mar 12, 2026, after the close
10-K filed Mar 12, 2026, 71 days after period end · 0001193125-26-104121
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.50M | $0.00 | $2.09M | $1.41M |
| Net Income | -$6.63M |
Bolt Biotherapeutics, Inc. · CIK 1641281 · Engraved from SEC EDGAR
| -$15.94M |
| -$17.90M |
| -$20.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.